サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1566962

人工膵臓デバイスシステム市場：デバイスタイプ別、エンドユーザー別：世界の機会分析と産業予測、2024～2033年

Artificial Pancreas Devices Systems Market By Device Type (Threshold Suspend Device Systems, Control-To-Range Systems, Control-To-Target Systems), By End User : Global Opportunity Analysis and Industry Forecast, 2024-2033

出版日
ページ情報
英文 280 Pages
納期
2～3営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
人工膵臓デバイスシステム市場：デバイスタイプ別、エンドユーザー別：世界の機会分析と産業予測、2024～2033年
出版日: 2024年07月10日
発行: Allied Market Research
ページ情報: 英文 280 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

人工膵臓デバイスシステム市場は、2023年に4億米ドルと評価され、2024～2033年までCAGR 8.8%で成長し、2033年には8億米ドルに達すると予測されています。

人工膵臓デバイスは、健康な膵臓のグルコース調節機能を模倣した医療機器で、最適な血糖値を維持することを目的としています。この医療技術は主に、糖尿病、特に1型糖尿病を患う人々の血糖値を監視・調整するために設計されています。これらのデバイスは、失われた機能を回復させ、人間の能力を高め、全体的な生活の質を向上させることを目的としています。

人工膵臓デバイスシステム市場の成長は、糖尿病、特に1型糖尿病の世界の有病率の憂慮すべき増加、人工膵臓デバイスシステムの利点に関する患者や医療プロバイダーの意識の上昇が主要要因です。IDF糖尿病アトラス第10版の2021年主要調査結果によると、約5億3,700万人の成人が糖尿病を患っています。この数は2030年には6億4,300万人、2045年には7億8,300万人に達すると推定されています。2021年には糖尿病が原因で約670万人が死亡したと報告されています。さらに、特に新興国における医療支出の増加により、より多くの患者が先進的な糖尿病管理技術を利用できるようになっています。同じ情報源によると、糖尿病は2021年に少なくとも9,660億米ドルの医療支出をもたらしました。さらに、人工膵臓デバイスシステムとデジタルヘルスプラットフォームとスマートフォンアプリケーションの統合は、患者エンゲージメントを強化し、より良い遠隔モニタリングと管理を可能にし、市場の主要な推進力として作用します。しかし、人工膵臓デバイスシステムに関連する高コストは、市場の成長を抑制します。さらに、ほとんどの国では人口のニーズを満たす適切な医療施設がなく、アクセスが限られていることが、市場の主要阻害要因として作用しています。逆に、センサー技術、インスリン送達システム、制御アルゴリズムの継続的な改善は、人工膵臓デバイスシステムの性能と信頼性を向上させ、予測期間中に世界市場の拡大に有益な機会を提供すると期待されています。加えて、糖尿病のケアと管理を改善することを目的としたイニシアチブの増加が、人工膵臓デバイスシステムの採用にインセンティブを与えています。例えば、世界保健機関は2021年4月にWHO世界糖尿病コンパクトというイニシアチブを立ち上げました。このイニシアチブは、糖尿病のリスクを低減し、糖尿病患者が手頃な価格で質の高い治療とケアを受けられるようにすることを目的としています。

人工膵臓デバイスシステム産業は、デバイスタイプ、エンドユーザー、地域に区分されます。デバイスタイプ別では、市場は閾値サスペンドデバイスシステム、CTR（control-to-range）システム、CTT（control-to-target）システムに分けられます。エンドユーザー別では、病院、クリニック、在宅医療に分けられます。地域別では、北米、欧州、アジア太平洋、ラテンアメリカ・中東・アフリカで分析されています。

主要調査結果

デバイスタイプ別では、閾値サスペンドデバイスシステムセグメントが2023年にシェアで市場を独占しました。

エンドユーザー別では、在宅ケアセグメントが2023年に最大シェアを獲得しました。

地域別では、北米が2023年の市場で支配的な地位を占めています。

本レポートのカスタマイズの可能性（追加費用とスケジュールが必要です。）

  • 規制ガイドライン
  • 顧客の関心に応じた企業プロファイルの追加
  • 国別または地域別の追加分析-市場規模と予測
  • 企業プロファイルの拡大リスト
  • 過去の市場データ

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場情勢

  • 市場の定義と範囲
  • 主要調査結果
    • 主要投資機会
    • 主要成功戦略
  • ポーターのファイブフォース分析
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会

第4章 人工膵臓デバイスシステム市場：デバイスタイプ別

  • 市場概要
  • 閾値サスペンドデバイスシステム
  • 範囲制御（CTR）システム
  • 標的制御（CTT）システム

第5章 人工膵臓デバイスシステム市場：エンドユーザー別

  • 市場概要
  • 病院
  • クリニック
  • 在宅医療

第6章 人工膵臓デバイスシステム市場：地域別

  • 市場概要
  • 北米
    • 主要市場動向と機会
    • 米国の人工膵臓デバイスシステム市場
    • カナダの人工膵臓デバイスシステム市場
    • メキシコの人工膵臓デバイスシステム市場
  • 欧州
    • 主要市場動向と機会
    • ドイツの人工膵臓デバイスシステム市場
    • フランスの人工膵臓デバイスシステム市場
    • 英国の人工膵臓デバイスシステム市場
    • イタリアの人工膵臓デバイスシステム市場
    • スペインの人工膵臓デバイスシステム市場
    • その他の欧州の人工膵臓デバイスシステム市場
  • アジア太平洋
    • 主要市場動向と機会
    • 日本の人工膵臓デバイスシステム市場
    • 中国の人工膵臓デバイスシステム市場
    • オーストラリアの人工膵臓デバイスシステム市場
    • インドの人工膵臓デバイスシステム市場
    • 韓国の人工膵臓デバイスシステム市場
    • その他のアジア太平洋の人工膵臓デバイスシステム市場
  • ラテンアメリカ・中東・アフリカ
    • 主要市場動向と機会
    • ブラジルの人工膵臓デバイスシステム市場
    • サウジアラビアの人工膵臓デバイスシステム市場
    • 南アフリカの人工膵臓デバイスシステム市場
    • その他のラテンアメリカ・中東・アフリカの人工膵臓デバイスシステム市場

第7章 競合情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10社の製品マッピング
  • 競合ダッシュボード
  • 競合ヒートマップ
  • 主要企業のポジショニング（2023年）

第8章 企業プロファイル

  • Medtronic Plc
  • Bigfoot Biomedical, Inc.
  • Johnson And Johnson
  • Tandem Diabetes Care, Inc.
  • Pancreum, Inc
  • TypeZero Technologies, LLC
  • Beta Bionics, Inc
  • Insulate Corporation
  • Diabeloop
  • Inreda Diabetic
目次
Product Code: A324367

The artificial pancreas devices systems market was valued at $0.4 billion in 2023, and is projected to reach $0.8 billion by 2033, growing at a CAGR of 8.8% from 2024 to 2033.

Artificial pancreas device is a medical device that mimics the glucose-regulating function of a healthy pancreas, aiming to maintain optimal blood sugar levels. This medical technology is primarily designed to monitor and regulate blood glucose levels in individuals suffering from diabetes, particularly those with type 1 diabetes. These devices aim to restore lost functions, enhance human capabilities, and improve overall quality of life.

The growth of the artificial pancreas devices systems market is majorly driven by alarming increase in global prevalence of diabetes, particularly type 1 diabetes and rise in awareness among patients and healthcare providers about the benefits of artificial pancreas systems. According to the 2021 key findings of IDF Diabetes Atlas 10th edition, approximately 537 million adults are suffering diabetes. This number is estimated to reach 643 million by 2030 and 783 million by 2045. Around 6.7 million deaths were reported due to diabetes in 2021. Moreover, increase in healthcare expenditure, particularly in emerging economies, allows more patients to access advanced diabetes management technologies. As per the same source, diabetes was responsible for at least $966 billion dollars in health expenditure in 2021. Furthermore, the integration of artificial pancreas devices systems with digital health platforms and smartphone applications enhances patient engagement and allows for better remote monitoring and management, which acts as the key driving force of the market. However, high cost associated with the artificial pancreas devices systems restrains the growth of the market. Moreover, lack of appropriate health facilities to meet population needs in most countries and limited access act as the key deterrent factors of the market. On the contrary, continuous improvements in sensor technology, insulin delivery systems, and control algorithms enhance the performance and reliability of artificial pancreas systems, which are expected to offer remunerative opportunities for the expansion of the global market during the forecast period. In addition, increase in initiatives aimed at improving diabetes care and management are providing incentives for the adoption of artificial pancreas systems. For instance, the World Health Organization launched an initiative in April 2021, WHO Global Diabetes Compact. The initiative aims to reduce the risk of diabetes and ensure that diabetic individuals have access to affordable and quality treatment and care.

The artificial pancreas devices systems industry is segmented into device type, end user, and region. By device type, the market is divided into threshold suspend device systems, control-to-range (CTR) systems, and control-to-target (CTT) systems. On the basis of end user, it is divided into hospitals, clinics, homecare. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By device type, the threshold suspend device systems segment dominated the market, in terms of share, in 2023.

Depending on end user, the homecare segment captured the largest share in 2023.

Region wise, North America holds a dominant position in the market in 2023.

Competition Analysis

Competitive analysis and profiles of the major players in the global artificial pancreas devices systems market include Medtronic plc, Bigfoot Biomedical, Inc., Johnson & Johnson, Tandem Diabetes Care, Inc., Pancreum, Inc, TypeZero Technologies, LLC, Beta Bionics, Inc, Insulate Corporation, Diabeloop, and Inreda Diabetic. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the competitive market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data

Key Market Segments

By Device Type

  • Threshold Suspend Device Systems
  • Control-To-Range (CTR) Systems
  • Control-To-Target (CTT) Systems

By End User

  • Hospitals
  • Clinics
  • Homecare

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Medtronic plc
    • Bigfoot Biomedical, Inc.
    • Johnson & Johnson
    • Tandem Diabetes Care, Inc.
    • Pancreum, Inc
    • TypeZero Technologies, LLC
    • Beta Bionics, Inc
    • Insulate Corporation
    • Diabeloop
    • Inreda Diabetic

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: ARTIFICIAL PANCREAS DEVICES SYSTEMS MARKET, BY DEVICE TYPE

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Device Type
  • 4.2. Threshold Suspend Device Systems
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Control-To-Range (CTR) Systems
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
  • 4.4. Control-To-Target (CTT) Systems
    • 4.4.1. Key Market Trends, Growth Factors and Opportunities
    • 4.4.2. Market Size and Forecast, By Region
    • 4.4.3. Market Share Analysis, By Country

CHAPTER 5: ARTIFICIAL PANCREAS DEVICES SYSTEMS MARKET, BY END USER

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By End User
  • 5.2. Hospitals
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Clinics
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country
  • 5.4. Homecare
    • 5.4.1. Key Market Trends, Growth Factors and Opportunities
    • 5.4.2. Market Size and Forecast, By Region
    • 5.4.3. Market Share Analysis, By Country

CHAPTER 6: ARTIFICIAL PANCREAS DEVICES SYSTEMS MARKET, BY REGION

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By Region
  • 6.2. North America
    • 6.2.1. Key Market Trends and Opportunities
    • 6.2.2. Market Size and Forecast, By Device Type
    • 6.2.3. Market Size and Forecast, By End User
    • 6.2.4. Market Size and Forecast, By Country
    • 6.2.5. U.S. Artificial Pancreas Devices Systems Market
      • 6.2.5.1. Market Size and Forecast, By Device Type
      • 6.2.5.2. Market Size and Forecast, By End User
    • 6.2.6. Canada Artificial Pancreas Devices Systems Market
      • 6.2.6.1. Market Size and Forecast, By Device Type
      • 6.2.6.2. Market Size and Forecast, By End User
    • 6.2.7. Mexico Artificial Pancreas Devices Systems Market
      • 6.2.7.1. Market Size and Forecast, By Device Type
      • 6.2.7.2. Market Size and Forecast, By End User
  • 6.3. Europe
    • 6.3.1. Key Market Trends and Opportunities
    • 6.3.2. Market Size and Forecast, By Device Type
    • 6.3.3. Market Size and Forecast, By End User
    • 6.3.4. Market Size and Forecast, By Country
    • 6.3.5. Germany Artificial Pancreas Devices Systems Market
      • 6.3.5.1. Market Size and Forecast, By Device Type
      • 6.3.5.2. Market Size and Forecast, By End User
    • 6.3.6. France Artificial Pancreas Devices Systems Market
      • 6.3.6.1. Market Size and Forecast, By Device Type
      • 6.3.6.2. Market Size and Forecast, By End User
    • 6.3.7. UK Artificial Pancreas Devices Systems Market
      • 6.3.7.1. Market Size and Forecast, By Device Type
      • 6.3.7.2. Market Size and Forecast, By End User
    • 6.3.8. Italy Artificial Pancreas Devices Systems Market
      • 6.3.8.1. Market Size and Forecast, By Device Type
      • 6.3.8.2. Market Size and Forecast, By End User
    • 6.3.9. Spain Artificial Pancreas Devices Systems Market
      • 6.3.9.1. Market Size and Forecast, By Device Type
      • 6.3.9.2. Market Size and Forecast, By End User
    • 6.3.10. Rest of Europe Artificial Pancreas Devices Systems Market
      • 6.3.10.1. Market Size and Forecast, By Device Type
      • 6.3.10.2. Market Size and Forecast, By End User
  • 6.4. Asia-Pacific
    • 6.4.1. Key Market Trends and Opportunities
    • 6.4.2. Market Size and Forecast, By Device Type
    • 6.4.3. Market Size and Forecast, By End User
    • 6.4.4. Market Size and Forecast, By Country
    • 6.4.5. Japan Artificial Pancreas Devices Systems Market
      • 6.4.5.1. Market Size and Forecast, By Device Type
      • 6.4.5.2. Market Size and Forecast, By End User
    • 6.4.6. China Artificial Pancreas Devices Systems Market
      • 6.4.6.1. Market Size and Forecast, By Device Type
      • 6.4.6.2. Market Size and Forecast, By End User
    • 6.4.7. Australia Artificial Pancreas Devices Systems Market
      • 6.4.7.1. Market Size and Forecast, By Device Type
      • 6.4.7.2. Market Size and Forecast, By End User
    • 6.4.8. India Artificial Pancreas Devices Systems Market
      • 6.4.8.1. Market Size and Forecast, By Device Type
      • 6.4.8.2. Market Size and Forecast, By End User
    • 6.4.9. South Korea Artificial Pancreas Devices Systems Market
      • 6.4.9.1. Market Size and Forecast, By Device Type
      • 6.4.9.2. Market Size and Forecast, By End User
    • 6.4.10. Rest of Asia-Pacific Artificial Pancreas Devices Systems Market
      • 6.4.10.1. Market Size and Forecast, By Device Type
      • 6.4.10.2. Market Size and Forecast, By End User
  • 6.5. LAMEA
    • 6.5.1. Key Market Trends and Opportunities
    • 6.5.2. Market Size and Forecast, By Device Type
    • 6.5.3. Market Size and Forecast, By End User
    • 6.5.4. Market Size and Forecast, By Country
    • 6.5.5. Brazil Artificial Pancreas Devices Systems Market
      • 6.5.5.1. Market Size and Forecast, By Device Type
      • 6.5.5.2. Market Size and Forecast, By End User
    • 6.5.6. Saudi Arabia Artificial Pancreas Devices Systems Market
      • 6.5.6.1. Market Size and Forecast, By Device Type
      • 6.5.6.2. Market Size and Forecast, By End User
    • 6.5.7. South Africa Artificial Pancreas Devices Systems Market
      • 6.5.7.1. Market Size and Forecast, By Device Type
      • 6.5.7.2. Market Size and Forecast, By End User
    • 6.5.8. Rest of LAMEA Artificial Pancreas Devices Systems Market
      • 6.5.8.1. Market Size and Forecast, By Device Type
      • 6.5.8.2. Market Size and Forecast, By End User

CHAPTER 7: COMPETITIVE LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top Winning Strategies
  • 7.3. Product Mapping of Top 10 Player
  • 7.4. Competitive Dashboard
  • 7.5. Competitive Heatmap
  • 7.6. Top Player Positioning, 2023

CHAPTER 8: COMPANY PROFILES

  • 8.1. Medtronic Plc
    • 8.1.1. Company Overview
    • 8.1.2. Key Executives
    • 8.1.3. Company Snapshot
    • 8.1.4. Operating Business Segments
    • 8.1.5. Product Portfolio
    • 8.1.6. Business Performance
    • 8.1.7. Key Strategic Moves and Developments
  • 8.2. Bigfoot Biomedical, Inc.
    • 8.2.1. Company Overview
    • 8.2.2. Key Executives
    • 8.2.3. Company Snapshot
    • 8.2.4. Operating Business Segments
    • 8.2.5. Product Portfolio
    • 8.2.6. Business Performance
    • 8.2.7. Key Strategic Moves and Developments
  • 8.3. Johnson And Johnson
    • 8.3.1. Company Overview
    • 8.3.2. Key Executives
    • 8.3.3. Company Snapshot
    • 8.3.4. Operating Business Segments
    • 8.3.5. Product Portfolio
    • 8.3.6. Business Performance
    • 8.3.7. Key Strategic Moves and Developments
  • 8.4. Tandem Diabetes Care, Inc.
    • 8.4.1. Company Overview
    • 8.4.2. Key Executives
    • 8.4.3. Company Snapshot
    • 8.4.4. Operating Business Segments
    • 8.4.5. Product Portfolio
    • 8.4.6. Business Performance
    • 8.4.7. Key Strategic Moves and Developments
  • 8.5. Pancreum, Inc
    • 8.5.1. Company Overview
    • 8.5.2. Key Executives
    • 8.5.3. Company Snapshot
    • 8.5.4. Operating Business Segments
    • 8.5.5. Product Portfolio
    • 8.5.6. Business Performance
    • 8.5.7. Key Strategic Moves and Developments
  • 8.6. TypeZero Technologies, LLC
    • 8.6.1. Company Overview
    • 8.6.2. Key Executives
    • 8.6.3. Company Snapshot
    • 8.6.4. Operating Business Segments
    • 8.6.5. Product Portfolio
    • 8.6.6. Business Performance
    • 8.6.7. Key Strategic Moves and Developments
  • 8.7. Beta Bionics, Inc
    • 8.7.1. Company Overview
    • 8.7.2. Key Executives
    • 8.7.3. Company Snapshot
    • 8.7.4. Operating Business Segments
    • 8.7.5. Product Portfolio
    • 8.7.6. Business Performance
    • 8.7.7. Key Strategic Moves and Developments
  • 8.8. Insulate Corporation
    • 8.8.1. Company Overview
    • 8.8.2. Key Executives
    • 8.8.3. Company Snapshot
    • 8.8.4. Operating Business Segments
    • 8.8.5. Product Portfolio
    • 8.8.6. Business Performance
    • 8.8.7. Key Strategic Moves and Developments
  • 8.9. Diabeloop
    • 8.9.1. Company Overview
    • 8.9.2. Key Executives
    • 8.9.3. Company Snapshot
    • 8.9.4. Operating Business Segments
    • 8.9.5. Product Portfolio
    • 8.9.6. Business Performance
    • 8.9.7. Key Strategic Moves and Developments
  • 8.10. Inreda Diabetic
    • 8.10.1. Company Overview
    • 8.10.2. Key Executives
    • 8.10.3. Company Snapshot
    • 8.10.4. Operating Business Segments
    • 8.10.5. Product Portfolio
    • 8.10.6. Business Performance
    • 8.10.7. Key Strategic Moves and Developments